JP2017531613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531613A5 JP2017531613A5 JP2017500335A JP2017500335A JP2017531613A5 JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5 JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017500335 A JP2017500335 A JP 2017500335A JP 2017531613 A5 JP2017531613 A5 JP 2017531613A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- subject
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059682P | 2014-10-03 | 2014-10-03 | |
| US62/059,682 | 2014-10-03 | ||
| PCT/US2015/053700 WO2016054494A1 (en) | 2014-10-03 | 2015-10-02 | Methods and compositions for treatment of conditions associated with elevated triglycerides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531613A JP2017531613A (ja) | 2017-10-26 |
| JP2017531613A5 true JP2017531613A5 (enExample) | 2018-11-08 |
| JP6680758B2 JP6680758B2 (ja) | 2020-04-15 |
Family
ID=55631597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500335A Expired - Fee Related JP6680758B2 (ja) | 2014-10-03 | 2015-10-02 | 上昇したトリグリセリドと関連する状態の治療のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10071139B2 (enExample) |
| EP (2) | EP3822287A1 (enExample) |
| JP (1) | JP6680758B2 (enExample) |
| AU (1) | AU2015327900B2 (enExample) |
| CA (1) | CA2954082A1 (enExample) |
| ES (1) | ES2819866T3 (enExample) |
| WO (1) | WO2016054494A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071139B2 (en) | 2014-10-03 | 2018-09-11 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| CN108779159B (zh) * | 2016-02-04 | 2022-12-30 | 瑞泽恩制药公司 | 具有经改造的angptl8基因的非人动物 |
| KR102456731B1 (ko) | 2016-03-03 | 2022-10-24 | 리제너론 파아마슈티컬스, 인크. | Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법 |
| CA3019635A1 (en) * | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| LT3439689T (lt) * | 2016-04-08 | 2021-11-10 | Regeneron Pharmaceuticals, Inc. | Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi |
| EA201991203A1 (ru) | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| CA3080148A1 (en) | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2425738T3 (es) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| AU2012267492A1 (en) | 2011-06-10 | 2014-01-09 | President And Fellows Of Harvard College | Modulation of pancreatic beta cell proliferation |
| US10259863B2 (en) * | 2013-01-11 | 2019-04-16 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| CA2925393C (en) | 2013-10-11 | 2023-03-07 | Dimiter Dimitrov | Tem8 antibodies and their use |
| US10071139B2 (en) | 2014-10-03 | 2018-09-11 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| EA201991203A1 (ru) | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| CA3080148A1 (en) | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
-
2015
- 2015-10-02 US US15/318,937 patent/US10071139B2/en active Active
- 2015-10-02 EP EP20185093.0A patent/EP3822287A1/en not_active Withdrawn
- 2015-10-02 WO PCT/US2015/053700 patent/WO2016054494A1/en not_active Ceased
- 2015-10-02 AU AU2015327900A patent/AU2015327900B2/en not_active Ceased
- 2015-10-02 EP EP15848061.6A patent/EP3201225B1/en active Active
- 2015-10-02 CA CA2954082A patent/CA2954082A1/en active Pending
- 2015-10-02 ES ES15848061T patent/ES2819866T3/es active Active
- 2015-10-02 JP JP2017500335A patent/JP6680758B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-06 US US16/056,068 patent/US10702587B2/en not_active Expired - Fee Related
-
2020
- 2020-05-29 US US16/888,249 patent/US20210015902A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531613A5 (enExample) | ||
| JP7365715B2 (ja) | 組織修復のための二重特異性治療用タンパク質 | |
| JP2014526441A5 (enExample) | ||
| JP6312765B2 (ja) | 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物 | |
| Chrysant et al. | Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors | |
| US10702587B2 (en) | Angiopoietin-like protein 8 polypeptide fragments and compositions thereof | |
| US10493135B2 (en) | Methods of treating tissue calcification | |
| JP2010513506A5 (enExample) | ||
| US20230265160A1 (en) | Therapeutic fusion proteins | |
| JP2009510999A (ja) | キメラ治療剤 | |
| Sarzani et al. | Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities | |
| JP2017500316A5 (enExample) | ||
| WO2013103972A1 (en) | Treatment of frailty syndrome and symptoms thereof | |
| CN102120755B (zh) | 一种棕色脂肪组织靶向性多肽及其应用 | |
| CN105079780B (zh) | 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用 | |
| JP2017509602A5 (enExample) | ||
| Moreno-Pérez et al. | Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney | |
| US20230357339A1 (en) | Development of Cell-Permeable Truncated SOCS3 SH2 Domain (CP-SD) Recombinant Protein for Anti-Obesity Agent | |
| Wagner et al. | Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): a randomised, double-blind, controlled trial | |
| Pala et al. | Noninvasive evaluation of a giant circumflex coronary artery aneurysm fistulized into the coronary sinus by multislice computed tomography Koroner sinüse fistülize dev sirkumfleks koroner arter anevrizmasının çokkesitli bilgisayarlı tomografi ile noninvaziv değerlendirilmesi | |
| JP2018500386A5 (enExample) |